Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCAR017 in relapsed/refractory indolent B-cell NHL
NCT04245839Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Jul 2020
- Primary completion
- Sep 2031
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of lisocabtagene maraleucel in follicular lymphoma (FL) and marginal zone lymphoma (MZL), sponsored by Celgene Corporation. Primary endpoint: Overall Response Rate at 60 months. Started Jul 2020; status: active, not recruiting.
02
Drugs
lisocabtagene maraleucel
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04245839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04245839.